Genor have two major categories of mAb drugs in our pipeline: biosimilars and novel antibodies. The targeted indications include cancer, autoimmune diseases and metabolic diseases.

There are more than 10 products in our R&D pipeline, first of which is a trastuzumab biosimilar currently conducting multi-center clinical trials in China and has completed Phase I clinical trial in Australia. It's shown that our product has very similar profile with the originator. Our second and third products, which are infliximab and adalimumab biosimilars, filed IND in China in 2012 and 2013, respectively. The adalimumab biosimilar also filed IND in South Korea in the end of 2013.